Paolo Bidoli
University of Milano-Bicocca
103 Papers
571 Citations
Paolo Bidoli is an academic researcher from University of Milano-Bicocca. The author has contributed to research in topics: Lung cancer & Population. The author has an hindex of 27, co-authored 103 publications.
Chat about Author
Papers
Exploratory subgroup analysis of patients (Pts) refractory to first-line (1L) chemotherapy from REVEL, a randomized phase III study of docetaxel (DOC) with ramucirumab (RAM) or placebo (PBO) for second-line (2L) treatment of stage IV non-small-cell lung cancer (NSCLC).
Martin Reck,Luis Paz-Ares,Paolo Bidoli,Federico Cappuzzo,Shaker R. Dakhil,Denis Moro-Sibilot,Hossein Borghaei,Melissa Lynne Johnson,Robert M. Jotte,Nathan A. Pennell,Frances A. Shepherd,Anne S. Tsao,Gebra Cuyun Carter,Faye Diehl,Ekaterine Alexandris,Pablo Lee,Annamaria Zimmermann,Joseph Treat,Andreas Sashegyi,Maurice Pérol +19 more
TL;DR: It is shown that the addition of RAM to DOC in the 2L treatment of pts with advanced NSCLC led to a consistent improvement in OS, PFS, and ORR, independent of histology, in the REVEL trial.
4
P3.02c-095 Italian Nivolumab Expanded Access Programme: Efficacy and Safety Data in Squamous Non-Small Cell Lung Cancer Patients: Topic: IT Clinical
Lucio Crinò,Paolo Bidoli,Angelo Delmonte,Francesco Grossi,Filippo de Marinis,Andrea Ardizzoni,Fabiana Vitiello,Marina Chiara Garassino,Hector Soto Parra,Enrico Cortesi,Frederico Cappuzzo,Michele Maio,Marcello Tiseo,Daniele Turci,Silvia Quadrini,Marco Bregni,Alessandro Morabito,Antonio Palla,Diana Giannarelli,Domenico Galetta +19 more
4
Updated Safety and Quality of Life (QOL) Results of Paramount Study: Maintenance Pemetrexed (PEM) Plus Best Supportive Care (BSC) vs Placebo (PBO) Plus Bsc Immediately Following Induction Treatment with Pem Plus Cisplatin (CP) for Advanced Nonsquamous Non-Small Cell Lung Cancer (NS-NSCLC)
J.L. Pujol,Luis Paz-Ares,M. Dediu,Michael Thomas,Paolo Bidoli,Jesus Corral,Nadia Chouaki,Carla Visseren-Grul,Annamaria Zimmermann,C. Gridelli +9 more
TL;DR: The PARAMOUNT trial showed that continuation maintenance therapy with pem after induction therapy with Pem plus CP significantly reduced the risk of disease progression and death in patients with advanced NS-NSCLC as discussed by the authors.
4
Gemcitabine-induced thrombocytosis as a potential predictive factor in non-small cell lung cancer: analysis of 318 patients.
Stefania Canova,Federica Cicchiello,Francesco Agustoni,Giampaolo Bianchini,Maria Ida Abbate,Paolo Bidoli,Diego Cortinovis +6 more
TL;DR: Thrombocytosis is neither a prognostic nor a predictive factor for PFS or OS in patients with advanced NSCLC treated with first-line gemcitabine-based chemotherapy in two Italian hospitals.
4
Trabectedin (T) as second line treatment option for patients with epithelioid malignant pleural mesothelioma (MPM) in progression following pemetrexed/platin-derivates chemotherapy: ATREUS trial.
Diego Cortinovis,Lital Hollander,Luciano Carlucci,Federica Grosso,Giovanni Luca Ceresoli,Ilaria Pacchetti,Paolo Andrea Zucali,Maurizio D'Incalci,Marcello Tiseo,Lorenzo Legramandi,Stefania Canova,Francesca Ugo,Maria Ida Abbate,Giacomo Taverna,Viola Cogliati,Paolo Bidoli +15 more
TL;DR: Systemic chemotherapy in MPM is inevitably followed by relapse, and response rates to second line treatment are limited, so patients need to be prepared for further treatment with a second line agent.
3